SI2833973T1 - Compounds useful as inhibitors of ATR kinase and their combination therapy - Google Patents
Compounds useful as inhibitors of ATR kinase and their combination therapy Download PDFInfo
- Publication number
- SI2833973T1 SI2833973T1 SI201330879T SI201330879T SI2833973T1 SI 2833973 T1 SI2833973 T1 SI 2833973T1 SI 201330879 T SI201330879 T SI 201330879T SI 201330879 T SI201330879 T SI 201330879T SI 2833973 T1 SI2833973 T1 SI 2833973T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cancer
- cell
- carcinoma
- group
- sarcoma
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 31
- 239000003112 inhibitor Substances 0.000 title claims abstract 7
- 108091000080 Phosphotransferase Proteins 0.000 title claims abstract 4
- 102000020233 phosphotransferase Human genes 0.000 title claims abstract 4
- 238000002648 combination therapy Methods 0.000 title claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims 96
- 210000004027 cell Anatomy 0.000 claims 88
- 201000011510 cancer Diseases 0.000 claims 84
- 206010039491 Sarcoma Diseases 0.000 claims 29
- 208000009956 adenocarcinoma Diseases 0.000 claims 25
- 206010025323 Lymphomas Diseases 0.000 claims 21
- 201000009030 Carcinoma Diseases 0.000 claims 19
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 16
- 208000020816 lung neoplasm Diseases 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 13
- 201000005202 lung cancer Diseases 0.000 claims 13
- 206010009944 Colon cancer Diseases 0.000 claims 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 10
- 201000002528 pancreatic cancer Diseases 0.000 claims 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 9
- 201000008808 Fibrosarcoma Diseases 0.000 claims 9
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 9
- 206010033128 Ovarian cancer Diseases 0.000 claims 9
- 201000011066 hemangioma Diseases 0.000 claims 9
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 9
- 206010008342 Cervix carcinoma Diseases 0.000 claims 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 8
- 201000010881 cervical cancer Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 7
- 201000002510 thyroid cancer Diseases 0.000 claims 7
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 claims 6
- 206010001233 Adenoma benign Diseases 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 6
- 208000032612 Glial tumor Diseases 0.000 claims 6
- 206010018338 Glioma Diseases 0.000 claims 6
- 208000002927 Hamartoma Diseases 0.000 claims 6
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 6
- 206010043276 Teratoma Diseases 0.000 claims 6
- 206010017758 gastric cancer Diseases 0.000 claims 6
- 208000005017 glioblastoma Diseases 0.000 claims 6
- 201000010536 head and neck cancer Diseases 0.000 claims 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims 6
- 208000024348 heart neoplasm Diseases 0.000 claims 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 6
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 6
- 201000007270 liver cancer Diseases 0.000 claims 6
- 208000014018 liver neoplasm Diseases 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- 206010027191 meningioma Diseases 0.000 claims 6
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical group FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 claims 6
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 6
- 201000011549 stomach cancer Diseases 0.000 claims 6
- -1 Η2ΑΧ Proteins 0.000 claims 6
- 206010005949 Bone cancer Diseases 0.000 claims 5
- 208000018084 Bone neoplasm Diseases 0.000 claims 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims 5
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 5
- 101001113440 Homo sapiens Poly [ADP-ribose] polymerase 2 Proteins 0.000 claims 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 5
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 claims 5
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims 5
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 claims 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 5
- 208000008383 Wilms tumor Diseases 0.000 claims 5
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 230000003211 malignant effect Effects 0.000 claims 5
- 201000011682 nervous system cancer Diseases 0.000 claims 5
- 201000000849 skin cancer Diseases 0.000 claims 5
- 208000013139 vaginal neoplasm Diseases 0.000 claims 5
- 102000000872 ATM Human genes 0.000 claims 4
- 208000003200 Adenoma Diseases 0.000 claims 4
- 201000003076 Angiosarcoma Diseases 0.000 claims 4
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 101000581289 Homo sapiens Microcephalin Proteins 0.000 claims 4
- 102100027632 Microcephalin Human genes 0.000 claims 4
- 230000007547 defect Effects 0.000 claims 4
- 206010016629 fibroma Diseases 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 201000010260 leiomyoma Diseases 0.000 claims 4
- 229960000572 olaparib Drugs 0.000 claims 4
- 201000008968 osteosarcoma Diseases 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 206010038038 rectal cancer Diseases 0.000 claims 4
- 201000001275 rectum cancer Diseases 0.000 claims 4
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims 4
- 210000001685 thyroid gland Anatomy 0.000 claims 4
- 230000001052 transient effect Effects 0.000 claims 4
- 229950011257 veliparib Drugs 0.000 claims 4
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 3
- 208000009458 Carcinoma in Situ Diseases 0.000 claims 3
- 208000005243 Chondrosarcoma Diseases 0.000 claims 3
- 208000006332 Choriocarcinoma Diseases 0.000 claims 3
- 206010010356 Congenital anomaly Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 201000005409 Gliomatosis cerebri Diseases 0.000 claims 3
- 206010018691 Granuloma Diseases 0.000 claims 3
- 206010019629 Hepatic adenoma Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 208000002404 Liver Cell Adenoma Diseases 0.000 claims 3
- 208000000172 Medulloblastoma Diseases 0.000 claims 3
- 208000015021 Meningeal Neoplasms Diseases 0.000 claims 3
- 206010027406 Mesothelioma Diseases 0.000 claims 3
- 208000006876 Multiple Endocrine Neoplasia Type 2b Diseases 0.000 claims 3
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims 3
- 208000010191 Osteitis Deformans Diseases 0.000 claims 3
- 208000027067 Paget disease of bone Diseases 0.000 claims 3
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 3
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 201000000582 Retinoblastoma Diseases 0.000 claims 3
- 208000005678 Rhabdomyoma Diseases 0.000 claims 3
- 201000010208 Seminoma Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 206010057644 Testis cancer Diseases 0.000 claims 3
- 206010046431 Urethral cancer Diseases 0.000 claims 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 3
- 206010048214 Xanthoma Diseases 0.000 claims 3
- 206010048215 Xanthomatosis Diseases 0.000 claims 3
- 208000002718 adenomatoid tumor Diseases 0.000 claims 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims 3
- 201000009036 biliary tract cancer Diseases 0.000 claims 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 3
- 208000016738 bone Paget disease Diseases 0.000 claims 3
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 3
- 201000002143 bronchus adenoma Diseases 0.000 claims 3
- 208000002458 carcinoid tumor Diseases 0.000 claims 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 208000006359 hepatoblastoma Diseases 0.000 claims 3
- 201000002735 hepatocellular adenoma Diseases 0.000 claims 3
- 210000003701 histiocyte Anatomy 0.000 claims 3
- 201000004933 in situ carcinoma Diseases 0.000 claims 3
- 210000002570 interstitial cell Anatomy 0.000 claims 3
- 208000022013 kidney Wilms tumor Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 210000002429 large intestine Anatomy 0.000 claims 3
- 206010024627 liposarcoma Diseases 0.000 claims 3
- 208000022006 malignant tumor of meninges Diseases 0.000 claims 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 3
- 201000008026 nephroblastoma Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000003388 osteoid osteoma Diseases 0.000 claims 3
- 208000008798 osteoma Diseases 0.000 claims 3
- 208000007312 paraganglioma Diseases 0.000 claims 3
- 201000001839 skull cancer Diseases 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 210000000278 spinal cord Anatomy 0.000 claims 3
- 208000001608 teratocarcinoma Diseases 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 3
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 206010046766 uterine cancer Diseases 0.000 claims 3
- 206010046885 vaginal cancer Diseases 0.000 claims 3
- CTLOSZHDGZLOQE-UHFFFAOYSA-N 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione Chemical compound O=C1C2=C3C=4C(OC)=CC=CC=4NC3=C3CCCC3=C2C(=O)N1CN1CCN(C)CC1 CTLOSZHDGZLOQE-UHFFFAOYSA-N 0.000 claims 2
- HYNBNUYQTQIHJK-UHFFFAOYSA-N 4-[[4-fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1CC(OC)CCN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F HYNBNUYQTQIHJK-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 2
- 206010008263 Cervical dysplasia Diseases 0.000 claims 2
- 239000012623 DNA damaging agent Substances 0.000 claims 2
- 102100039524 DNA endonuclease RBBP8 Human genes 0.000 claims 2
- 102100039116 DNA repair protein RAD50 Human genes 0.000 claims 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 2
- 102100033996 Double-strand break repair protein MRE11 Human genes 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000007659 Fibroadenoma Diseases 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 208000007569 Giant Cell Tumors Diseases 0.000 claims 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 2
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 claims 2
- 101000591400 Homo sapiens Double-strand break repair protein MRE11 Proteins 0.000 claims 2
- 101000581326 Homo sapiens Mediator of DNA damage checkpoint protein 1 Proteins 0.000 claims 2
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 claims 2
- 101000981336 Homo sapiens Nibrin Proteins 0.000 claims 2
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims 2
- 206010024612 Lipoma Diseases 0.000 claims 2
- 102100027643 Mediator of DNA damage checkpoint protein 1 Human genes 0.000 claims 2
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 claims 2
- 102100024403 Nibrin Human genes 0.000 claims 2
- 108700020796 Oncogene Proteins 0.000 claims 2
- 208000000035 Osteochondroma Diseases 0.000 claims 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 2
- 101150097169 RBBP8 gene Proteins 0.000 claims 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims 2
- 102100029538 Structural maintenance of chromosomes protein 1A Human genes 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- 102000000504 Tumor Suppressor p53-Binding Protein 1 Human genes 0.000 claims 2
- 108010041385 Tumor Suppressor p53-Binding Protein 1 Proteins 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 210000004100 adrenal gland Anatomy 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 201000003149 breast fibroadenoma Diseases 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims 2
- 201000005217 chondroblastoma Diseases 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical group COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229950002133 iniparib Drugs 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 2
- 230000005865 ionizing radiation Effects 0.000 claims 2
- 210000000867 larynx Anatomy 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- HAVFFEMDLROBGI-UHFFFAOYSA-N m8926c7ilx Chemical compound C1CC(O)CCN1CC1=CC=C(OC=2C3=C(C(NN=C33)=O)C=CC=2)C3=C1 HAVFFEMDLROBGI-UHFFFAOYSA-N 0.000 claims 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 2
- 229960001428 mercaptopurine Drugs 0.000 claims 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 210000003660 reticulum Anatomy 0.000 claims 2
- 229950004707 rucaparib Drugs 0.000 claims 2
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 108010004731 structural maintenance of chromosome protein 1 Proteins 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 208000013066 thyroid gland cancer Diseases 0.000 claims 2
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 210000005239 tubule Anatomy 0.000 claims 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical group C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 claims 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- 201000005262 Chondroma Diseases 0.000 claims 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- 206010048832 Colon adenoma Diseases 0.000 claims 1
- 108010068192 Cyclin A Proteins 0.000 claims 1
- 102000003909 Cyclin E Human genes 0.000 claims 1
- 108090000257 Cyclin E Proteins 0.000 claims 1
- 102100025191 Cyclin-A2 Human genes 0.000 claims 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000005917 Exostoses Diseases 0.000 claims 1
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 claims 1
- 206010073153 Familial medullary thyroid cancer Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 1
- 101710113436 GTPase KRas Proteins 0.000 claims 1
- 102100039788 GTPase NRas Human genes 0.000 claims 1
- 102100034533 Histone H2AX Human genes 0.000 claims 1
- 101001060231 Homo sapiens F-box/WD repeat-containing protein 7 Proteins 0.000 claims 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 1
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 claims 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims 1
- 241000187747 Streptomyces Species 0.000 claims 1
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 1
- 235000011941 Tilia x europaea Nutrition 0.000 claims 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims 1
- 206010062129 Tongue neoplasm Diseases 0.000 claims 1
- 229930183665 actinomycin Natural products 0.000 claims 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims 1
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 1
- 229960000473 altretamine Drugs 0.000 claims 1
- 229960003896 aminopterin Drugs 0.000 claims 1
- 229960002550 amrubicin Drugs 0.000 claims 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims 1
- 150000001541 aziridines Chemical class 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 210000002449 bone cell Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 229960003261 carmofur Drugs 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960002436 cladribine Drugs 0.000 claims 1
- 229960000928 clofarabine Drugs 0.000 claims 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- PZAQDVNYNJBUTM-UHFFFAOYSA-L cyclohexane-1,2-diamine;7,7-dimethyloctanoate;platinum(2+) Chemical compound [Pt+2].NC1CCCCC1N.CC(C)(C)CCCCCC([O-])=O.CC(C)(C)CCCCCC([O-])=O PZAQDVNYNJBUTM-UHFFFAOYSA-L 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 201000003914 endometrial carcinoma Diseases 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960001842 estramustine Drugs 0.000 claims 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims 1
- 201000010934 exostosis Diseases 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- 239000004571 lime Substances 0.000 claims 1
- 229960002247 lomustine Drugs 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 201000004593 malignant giant cell tumor Diseases 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960005485 mitobronitol Drugs 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- VIJMMQUAJQEELS-UHFFFAOYSA-N n,n-bis(ethenyl)ethenamine Chemical compound C=CN(C=C)C=C VIJMMQUAJQEELS-UHFFFAOYSA-N 0.000 claims 1
- 229950007221 nedaplatin Drugs 0.000 claims 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 229960001420 nimustine Drugs 0.000 claims 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 229960002340 pentostatin Drugs 0.000 claims 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 1
- 229950005566 picoplatin Drugs 0.000 claims 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims 1
- 208000024724 pineal body neoplasm Diseases 0.000 claims 1
- 210000004560 pineal gland Anatomy 0.000 claims 1
- 201000004123 pineal gland cancer Diseases 0.000 claims 1
- 229960001221 pirarubicin Drugs 0.000 claims 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 1
- 229960000624 procarbazine Drugs 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 230000000113 radiomimetic effect Effects 0.000 claims 1
- 229960004432 raltitrexed Drugs 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims 1
- 229950009213 rubitecan Drugs 0.000 claims 1
- 229960005399 satraplatin Drugs 0.000 claims 1
- 190014017285 satraplatin Chemical compound 0.000 claims 1
- 229960003440 semustine Drugs 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 231100000489 sensitizer Toxicity 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229960001674 tegafur Drugs 0.000 claims 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- 229960001278 teniposide Drugs 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 150000004654 triazenes Chemical class 0.000 claims 1
- 229950002860 triplatin tetranitrate Drugs 0.000 claims 1
- 190014017283 triplatin tetranitrate Chemical compound 0.000 claims 1
- 208000022271 tubular adenoma Diseases 0.000 claims 1
- 229960001055 uracil mustard Drugs 0.000 claims 1
- 229960000653 valrubicin Drugs 0.000 claims 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 1
- 208000009540 villous adenoma Diseases 0.000 claims 1
- 229950009268 zinostatin Drugs 0.000 claims 1
- 229960000641 zorubicin Drugs 0.000 claims 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 238000010835 comparative analysis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000031146 intracellular signal transduction Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261620717P | 2012-04-05 | 2012-04-05 | |
| EP13728551.6A EP2833973B1 (en) | 2012-04-05 | 2013-04-05 | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| PCT/US2013/035466 WO2013152298A1 (en) | 2012-04-05 | 2013-04-05 | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2833973T1 true SI2833973T1 (en) | 2018-04-30 |
Family
ID=48614105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201330879T SI2833973T1 (en) | 2012-04-05 | 2013-04-05 | Compounds useful as inhibitors of ATR kinase and their combination therapy |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20140044802A1 (Direct) |
| EP (2) | EP3311816A1 (Direct) |
| JP (4) | JP2015515478A (Direct) |
| CN (2) | CN108478577A (Direct) |
| AU (2) | AU2013243291B2 (Direct) |
| CA (1) | CA2869309C (Direct) |
| DK (1) | DK2833973T3 (Direct) |
| ES (1) | ES2654670T3 (Direct) |
| HK (1) | HK1205028A1 (Direct) |
| HR (1) | HRP20171915T1 (Direct) |
| HU (1) | HUE035253T2 (Direct) |
| IN (1) | IN2014KN02410A (Direct) |
| LT (1) | LT2833973T (Direct) |
| MX (1) | MX358818B (Direct) |
| NO (1) | NO2885404T3 (Direct) |
| NZ (3) | NZ726671A (Direct) |
| PL (1) | PL2833973T3 (Direct) |
| PT (1) | PT2833973T (Direct) |
| RS (1) | RS56673B1 (Direct) |
| SI (1) | SI2833973T1 (Direct) |
| TW (2) | TWI644672B (Direct) |
| WO (1) | WO2013152298A1 (Direct) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3013000C (en) | 2008-12-19 | 2022-12-13 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| MX2012013081A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
| EP3608316A1 (en) | 2011-09-30 | 2020-02-12 | Vertex Pharmaceuticals Incorporated | Deuterated derivatives of an inhibitor of atr kinase |
| WO2013049859A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
| IN2014KN02410A (Direct) | 2012-04-05 | 2015-05-01 | Vertex Pharma | |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| PL3808749T3 (pl) | 2012-12-07 | 2023-07-10 | Vertex Pharmaceuticals Incorporated | Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych |
| BR112015017331B1 (pt) | 2013-01-23 | 2022-01-11 | Astrazeneca Ab | Compostos de formula i, forma cristalina, uso dos compostos, combinação e composição |
| EP3077397B1 (en) | 2013-12-06 | 2019-09-18 | Vertex Pharmaceuticals Inc. | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
| RU2020110358A (ru) | 2014-06-05 | 2020-04-30 | Вертекс Фармасьютикалз Инкорпорейтед | Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор- пиридин-3-ил]-пиразоло[1,5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы |
| JP6936007B2 (ja) | 2014-06-17 | 2021-09-15 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法 |
| TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| EP3182975B1 (en) * | 2014-08-22 | 2025-10-01 | pharma& Schweiz GmbH | High dosage strength tablets of rucaparib |
| US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| EP3399983A1 (en) | 2016-01-08 | 2018-11-14 | The Institute of Cancer Research: Royal Cancer Hospital | Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer |
| KR102461219B1 (ko) | 2016-01-11 | 2022-10-31 | 메리맥 파마슈티컬즈, 인크. | 혈관확장성 운동실조증 및 Rad3-관련 단백질(ATR)의 억제 |
| CN116655730A (zh) | 2016-06-01 | 2023-08-29 | 雅斯娜 | 用于治疗多种疾病的n-己酸-l-酪氨酸-l-异亮氨酸-(6)-氨基己酰胺的衍生物 |
| WO2018153972A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and antiandrogens |
| TW201840319A (zh) | 2017-02-24 | 2018-11-16 | 德商拜耳廠股份有限公司 | Atr激酶抑制劑與鐳-223鹽之組合 |
| JOP20190197A1 (ar) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر |
| WO2018187479A1 (en) | 2017-04-04 | 2018-10-11 | Case Western Reserve University | Method of modulating ribonucleotide reductase |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| EP3661560B1 (en) | 2017-08-04 | 2025-02-26 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| EP3720973A1 (en) | 2017-12-08 | 2020-10-14 | Bayer Aktiengesellschaft | Predictive markers for atr kinase inhibitors |
| CN113286614A (zh) | 2018-09-26 | 2021-08-20 | 默克专利股份有限公司 | 用于治疗癌症的pd-1拮抗剂、atr抑制剂和铂化物质的组合 |
| AU2019360608A1 (en) | 2018-10-15 | 2021-06-03 | Merck Patent Gmbh | Combination therapy utilizing DNA alkylating agents and ATR inhibitors |
| EP3866805A1 (en) | 2018-10-16 | 2021-08-25 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
| EP3873905A4 (en) | 2018-10-30 | 2022-08-17 | Repare Therapeutics Inc. | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING COMPOUNDS AND THEIR USE AS ATR KINASE INHIBITORS |
| WO2021021741A1 (en) * | 2019-07-26 | 2021-02-04 | Health Research, Inc. | Treatment of p53-deficient cancers |
| US12128050B2 (en) | 2020-11-10 | 2024-10-29 | New Mexico Tech University Research Park Corporation | KP372-1-induced DNA damage as a chemotherapeutic approach to treat cancer |
| CN117024413B (zh) * | 2023-10-07 | 2024-01-09 | 天津匠新致成科技有限公司 | 3-氨基吡嗪-2-甲酰胺类靶向蛋白水解嵌合体及其制备方法、药物组合物和应用 |
Family Cites Families (218)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309430A (en) | 1980-06-27 | 1982-01-05 | Merck & Co., Inc. | Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same |
| JPS62270623A (ja) | 1985-12-07 | 1987-11-25 | Daicel Chem Ind Ltd | ビス（４−アミノフエニル）ピラジンおよびその製法、ならびにポリイミドおよびその製法 |
| JPS63208520A (ja) | 1987-02-26 | 1988-08-30 | Terumo Corp | ピラジン誘導体を含有する血小板凝集抑制剤 |
| US5329012A (en) | 1987-10-29 | 1994-07-12 | The Research Foundation Of State University Of New York | Bis(acyloxmethyl)imidazole compounds |
| JPH0272370A (ja) | 1988-09-07 | 1990-03-12 | Konica Corp | 電子写真感光体 |
| JPH0272372A (ja) | 1988-09-07 | 1990-03-12 | Konica Corp | 電子写真感光体 |
| JPH0374370A (ja) | 1989-08-16 | 1991-03-28 | Terumo Corp | ピラジン誘導体およびこれを含有する血小板凝集抑制剤または抗炎症剤 |
| JP2597917B2 (ja) | 1990-04-26 | 1997-04-09 | 富士写真フイルム株式会社 | 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料 |
| US5572248A (en) | 1994-09-19 | 1996-11-05 | Teleport Corporation | Teleconferencing method and system for providing face-to-face, non-animated teleconference environment |
| EP0914318A1 (en) | 1996-05-11 | 1999-05-12 | Kings College London | Pyrazines |
| JP4026876B2 (ja) | 1996-09-05 | 2007-12-26 | 日本食品化工株式会社 | 発光性シクロデキストリン誘導体及びその製造方法 |
| JP2002241379A (ja) | 1997-03-21 | 2002-08-28 | Dainippon Pharmaceut Co Ltd | ３−オキサジアゾリルキノキサリン誘導体 |
| WO1999044609A1 (en) | 1998-03-03 | 1999-09-10 | Merck & Co., Inc. | FUSED PIPERIDINE SUBSTITUTED ARYLSULFONAMIDES AS β3-AGONISTS |
| DE19826671A1 (de) | 1998-06-16 | 1999-12-23 | Hoechst Schering Agrevo Gmbh | 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
| KR20010071936A (ko) | 1998-07-16 | 2001-07-31 | 시오노 요시히코 | 항종양 활성을 갖는 피리미딘 유도체 |
| US7023913B1 (en) | 2000-06-14 | 2006-04-04 | Monroe David A | Digital security multimedia sensor |
| DK1150999T3 (da) | 1999-02-05 | 2006-10-30 | Debiopharm Sa | Cyclosporinderivater og fremgangsmåde til fremstilling deraf |
| US6738073B2 (en) | 1999-05-12 | 2004-05-18 | Imove, Inc. | Camera system with both a wide angle view and a high resolution view |
| EP1377554A1 (en) | 1999-06-16 | 2004-01-07 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
| US7015954B1 (en) | 1999-08-09 | 2006-03-21 | Fuji Xerox Co., Ltd. | Automatic video system using multiple cameras |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| DE60037905T2 (de) | 1999-12-17 | 2009-01-29 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Pyrazin-basierte hemmer der glycogen-synthase-kinase 3 |
| US6849660B1 (en) | 2000-08-01 | 2005-02-01 | Isis Pharmaceuticals, Inc. | Antimicrobial biaryl compounds |
| US6829391B2 (en) | 2000-09-08 | 2004-12-07 | Siemens Corporate Research, Inc. | Adaptive resolution system and method for providing efficient low bit rate transmission of image data for distributed applications |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| US8085293B2 (en) | 2001-03-14 | 2011-12-27 | Koninklijke Philips Electronics N.V. | Self adjusting stereo camera system |
| US6759657B2 (en) | 2001-03-27 | 2004-07-06 | Kabushiki Kaisha Toshiba | Infrared sensor |
| WO2002080899A1 (fr) | 2001-03-30 | 2002-10-17 | Eisai Co., Ltd. | Agent de traitement de maladie digestive |
| US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
| WO2002089738A2 (en) | 2001-05-08 | 2002-11-14 | Yale University | Proteomimetic compounds and methods |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| SE0102438D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| WO2003026572A2 (en) | 2001-09-26 | 2003-04-03 | Merck & Co., Inc. | Crystalline forms of ertapenem sodium |
| GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| US6992087B2 (en) | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| ATE447561T1 (de) | 2001-11-21 | 2009-11-15 | Pharmacia & Upjohn Co Llc | Substituierte aryl 1,4-pyrazin derivate |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| EP1472245A2 (en) | 2002-02-06 | 2004-11-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors of gsk-3 |
| WO2003076422A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| US7043079B2 (en) | 2002-04-25 | 2006-05-09 | Microsoft Corporation | “Don't care” pixel interpolation |
| GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| CA2484209C (en) | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| CN1656079A (zh) | 2002-05-31 | 2005-08-17 | 卫材株式会社 | 吡唑化合物和含有该化合物的药物组合物 |
| AU2003245669A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| WO2004000318A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
| WO2004033431A2 (en) | 2002-10-04 | 2004-04-22 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
| US20040075741A1 (en) | 2002-10-17 | 2004-04-22 | Berkey Thomas F. | Multiple camera image multiplexer |
| US7385626B2 (en) | 2002-10-21 | 2008-06-10 | Sarnoff Corporation | Method and system for performing surveillance |
| US20040100560A1 (en) | 2002-11-22 | 2004-05-27 | Stavely Donald J. | Tracking digital zoom in a digital video camera |
| SE0203754D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| SE0203752D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| MXPA05009063A (es) | 2003-02-26 | 2005-12-12 | Sugen Inc | Compuestos de aminoheteroarilo como inhibidores de proteina cinasa. |
| US7684624B2 (en) | 2003-03-03 | 2010-03-23 | Smart Technologies Ulc | System and method for capturing images of a target area on which information is recorded |
| MXPA05009245A (es) | 2003-03-11 | 2005-10-19 | Pfizer Prod Inc | Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf). |
| US7459454B2 (en) | 2003-03-21 | 2008-12-02 | Smithkline Beecham Corporation | Aminopyrazine derivatives and compositions |
| EP1608622A4 (en) | 2003-03-24 | 2009-04-01 | Merck & Co Inc | BIARYLSUBSTITUTED 6-LOW HETEROCYCLES AS SODIUM CHANNEL BLOCKERS |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| GB2400514B (en) | 2003-04-11 | 2006-07-26 | Hewlett Packard Development Co | Image capture method |
| AU2004240586A1 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists |
| WO2004103991A1 (en) | 2003-05-20 | 2004-12-02 | 'chemical Diversity Research Institute', Ltd. | 2-substituted piperidines, focused library and a pharmaceutical compound |
| US20050123902A1 (en) | 2003-05-21 | 2005-06-09 | President And Fellows Of Harvard College | Human papillomavirus inhibitors |
| PE20050206A1 (es) | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| US7986339B2 (en) | 2003-06-12 | 2011-07-26 | Redflex Traffic Systems Pty Ltd | Automated traffic violation monitoring and reporting system with combined video and still-image data |
| JP2005020227A (ja) | 2003-06-25 | 2005-01-20 | Pfu Ltd | 画像圧縮装置 |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| US7807696B2 (en) | 2003-10-07 | 2010-10-05 | The Feinstein Institute For Medical Research | Isoxazole and isothiazole compounds useful in the treatment of inflammation |
| US20050116968A1 (en) | 2003-12-02 | 2005-06-02 | John Barrus | Multi-capability display |
| EP1694670A1 (en) | 2003-12-16 | 2006-08-30 | GPC Biotech AG | Pyrazine derivatives as effective compounds against infectious diseases |
| EP1715867A4 (en) | 2004-02-12 | 2009-04-15 | Merck & Co Inc | BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 |
| US20050276765A1 (en) | 2004-06-10 | 2005-12-15 | Paul Nghiem | Preventing skin damage |
| JP2008502687A (ja) | 2004-06-14 | 2008-01-31 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| SG156685A1 (en) | 2004-07-27 | 2009-11-26 | Sgx Pharmaceuticals Inc | Fused ring heterocycle kinase modulators |
| US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| BRPI0513915A (pt) | 2004-08-26 | 2008-05-20 | Pfizer | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase |
| CA2578075A1 (en) | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
| US7730406B2 (en) | 2004-10-20 | 2010-06-01 | Hewlett-Packard Development Company, L.P. | Image processing system and method |
| US7705042B2 (en) | 2004-10-22 | 2010-04-27 | Janssen Pharmaceutica Nv | Class of arylamide compounds useful as inhibitors of c-fms kinase |
| EP1828144A2 (en) | 2004-11-12 | 2007-09-05 | OSI Pharmaceuticals, Inc. | Integrin antagonists useful as anticancer agents |
| CA2587926A1 (en) | 2004-11-22 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Bicyclic inhibitors or rho kinase |
| JP4810669B2 (ja) | 2004-11-25 | 2011-11-09 | コニカミノルタホールディングス株式会社 | 有機エレクトロルミネッセンス素子、表示装置及び照明装置 |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| CN101102773B (zh) | 2004-12-27 | 2010-10-27 | 爱尔康公司 | 治疗青光眼和其他rho激酶-介导疾病的氨基吡嗪类似物 |
| GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| PE20061093A1 (es) | 2005-02-16 | 2006-11-10 | Schering Corp | Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3 |
| ATE524467T1 (de) | 2005-04-25 | 2011-09-15 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| AU2006258101A1 (en) | 2005-06-09 | 2006-12-21 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
| US8153804B2 (en) | 2005-08-02 | 2012-04-10 | Lexicon Pharmaceuticals, Inc. | Aryl pyridines and methods of their use |
| WO2007015632A1 (en) | 2005-08-04 | 2007-02-08 | Cgk Co., Ltd. | Atm and atr inhibitor |
| US7394926B2 (en) | 2005-09-30 | 2008-07-01 | Mitutoyo Corporation | Magnified machine vision user interface |
| US7806604B2 (en) | 2005-10-20 | 2010-10-05 | Honeywell International Inc. | Face detection and tracking in a wide field of view |
| AR056786A1 (es) | 2005-11-10 | 2007-10-24 | Smithkline Beecham Corp | Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com |
| KR101135310B1 (ko) | 2005-12-01 | 2012-04-12 | 에프. 호프만-라 로슈 아게 | Ｌ-ｃｐｔ1 억제제로서의 헤테로아릴 치환된 피페리딘유도체 |
| WO2007066805A1 (ja) | 2005-12-09 | 2007-06-14 | Meiji Seika Kaisha, Ltd. | リンコマイシン誘導体およびこれを有効成分とする抗菌剤 |
| BRPI0620668A2 (pt) | 2005-12-14 | 2011-11-22 | Du Pont | composto da fórmula 1, composição que compreende composto, composição de controle de pragas invertebradas, composição de pulverização, composição de isca, dispositivo de armadilha, métodos de controle de pragas invertebradas, método de controle de baratas, formigas ou cupins e método de proteção de sementes contra pragas invertebradas |
| EP1962853A1 (en) | 2005-12-22 | 2008-09-03 | Alcon Research, Ltd. | (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| ITMI20060311A1 (it) | 2006-02-21 | 2007-08-22 | Btsr Int Spa | Dispositivo perfezionato di alimentazione di filo o filatio ad una macchina tessile e metodo per attuare tale alimentazione |
| GB0603684D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
| TW200800203A (en) | 2006-03-08 | 2008-01-01 | Astrazeneca Ab | New use |
| WO2007111904A2 (en) | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors for the treatment of proliferative disorders |
| US7574131B2 (en) | 2006-03-29 | 2009-08-11 | Sunvision Scientific Inc. | Object detection system and method |
| CN101454314A (zh) | 2006-03-31 | 2009-06-10 | 先灵公司 | 激酶抑制剂 |
| US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| CA2655857C (en) | 2006-06-22 | 2014-12-02 | Mallinckrodt Inc. | Pyrazine derivatives with extended conjugation and uses thereof |
| CN101472912A (zh) | 2006-06-22 | 2009-07-01 | 比奥维特罗姆上市公司 | 作为mnk激酶抑制剂的吡啶和吡嗪衍生物 |
| EP1900727A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
| AU2007302263A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as P13K lipid kinase inhibitors |
| GB0619342D0 (en) | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
| KR101107896B1 (ko) | 2006-10-04 | 2012-01-25 | 에프. 호프만-라 로슈 아게 | 고 밀도 지단백질(ｈｄｌ)-콜레스테롤 상승제로서 3-피리딘카복스아마이드 및 2-피라진카복스아마이드 유도체 |
| BRPI0717767A2 (pt) | 2006-10-19 | 2013-11-12 | Signal Pharm Llc | Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula de expressa a dita quinase |
| WO2008060907A2 (en) | 2006-11-10 | 2008-05-22 | Bristol-Myers Squibb Company | Pyrrolo-pyridine kinase inhibitors |
| US20080132698A1 (en) | 2006-11-30 | 2008-06-05 | University Of Ottawa | Use of N-oxide compounds in coupling reactions |
| CL2007003627A1 (es) | 2006-12-15 | 2008-07-25 | Bayer Schering Pharma Ag | Compuestos derivados de 3-h-pirazolopiridinas; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades de crecimiento vascular desregulado tal como leucemia mielogena aguda, retinopatia, artritis reumatoide, psorias |
| CA2672438A1 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
| GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| CA2676173A1 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| JP5330274B2 (ja) | 2007-03-01 | 2013-10-30 | ノバルティス アーゲー | Ｐｉｍキナーゼ阻害剤およびその使用方法 |
| CA2683180A1 (en) | 2007-04-10 | 2008-10-16 | Bayer Cropscience Ag | Insecticidal aryl isoxazoline derivatives |
| JP2008260691A (ja) | 2007-04-10 | 2008-10-30 | Bayer Cropscience Ag | 殺虫性アリールイソオキサゾリン誘導体 |
| US7592342B2 (en) | 2007-05-10 | 2009-09-22 | Smithkline Beecham Corporation | Quinoxaline derivatives as PI3 kinase inhibitors |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US20100249112A1 (en) * | 2007-05-25 | 2010-09-30 | Astrazeneca R&D | Combination of chk and parp inhibitors for the treatment of cancers |
| UY31137A1 (es) | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
| EP2012409A2 (en) | 2007-06-19 | 2009-01-07 | Hitachi, Ltd. | Rotating electrical machine |
| WO2008156174A1 (ja) | 2007-06-21 | 2008-12-24 | Taisho Pharmaceutical Co., Ltd. | ピラジンアミド化合物 |
| BRPI0813212A2 (pt) | 2007-06-26 | 2014-12-23 | Lexicon Pharmaceuticals Inc | Métodos de tratamento de doenças e distúrbios mediados por serotonina |
| CN101808518A (zh) | 2007-06-27 | 2010-08-18 | 默沙东公司 | 作为组蛋白脱乙酰酶抑制剂的吡啶基和嘧啶基衍生物 |
| GB0713259D0 (en) | 2007-07-09 | 2007-08-15 | Astrazeneca Ab | Pyrazine derivatives 954 |
| NZ582708A (en) | 2007-07-19 | 2012-04-27 | Schering Corp | Heterocyclic amide compounds as protein kinase inhibitors |
| AU2008275891B2 (en) | 2007-07-19 | 2013-10-10 | H.Lundbeck A/S | 5-membered heterocyclic amides and related compounds |
| WO2009016460A2 (en) | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
| WO2009024825A1 (en) | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
| US8415358B2 (en) | 2007-09-17 | 2013-04-09 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| JP2011500778A (ja) | 2007-10-25 | 2011-01-06 | アストラゼネカ・アクチエボラーグ | ピリジン及びピラジン誘導体−０８３ |
| EP2265270A1 (en) | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
| JP5485178B2 (ja) | 2008-02-25 | 2014-05-07 | エフ．ホフマン−ラ ロシュ アーゲー | ピロロピラジンキナーゼ阻害剤 |
| EP2250172B1 (en) | 2008-02-25 | 2011-08-31 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
| PT2247592E (pt) | 2008-02-25 | 2011-11-03 | Hoffmann La Roche | Inibidores de pirrolpirazina-cinase |
| WO2009106444A1 (en) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
| EP2265574A1 (en) | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
| GB0814364D0 (en) | 2008-08-05 | 2008-09-10 | Eisai London Res Lab Ltd | Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase |
| JP5576370B2 (ja) | 2008-08-06 | 2014-08-20 | ファイザー・インク | Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物 |
| KR101846029B1 (ko) | 2008-08-06 | 2018-04-06 | 메디베이션 테크놀로지즈 엘엘씨 | 폴리(ａｄｐ-리보오스)폴리머라아제 (ｐａｒｐ)의 디히드로피리도프탈라지논 억제제 |
| JP2012506381A (ja) | 2008-10-21 | 2012-03-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｃ−ＭＥＴタンパク質キナーゼ阻害剤 |
| RU2011123647A (ru) | 2008-11-10 | 2012-12-20 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, полезные в качестве ингибиторов atr киназы |
| ES2554375T3 (es) | 2008-11-25 | 2015-12-18 | University Of Rochester | Inhibidores de las MLK y métodos de uso |
| SG171956A1 (en) | 2008-12-05 | 2011-07-28 | Hoffmann La Roche | Pyrrolopyrazinyl urea kinase inhibitors |
| CA3013000C (en) | 2008-12-19 | 2022-12-13 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
| CN102325767B (zh) | 2008-12-22 | 2014-05-14 | 阵列生物制药公司 | 7-苯氧基色满羧酸衍生物 |
| TW201028410A (en) | 2008-12-22 | 2010-08-01 | Astrazeneca Ab | Chemical compounds 610 |
| WO2010075376A2 (en) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
| SG173027A1 (en) | 2009-01-30 | 2011-08-29 | Toyama Chemical Co Ltd | N-acyl anthranilic acid derivative or salt thereof |
| JP5353279B2 (ja) | 2009-02-06 | 2013-11-27 | Ｊｎｃ株式会社 | セレンテラミド又はその類縁体の製造方法 |
| WO2010093425A1 (en) | 2009-02-11 | 2010-08-19 | Sepracor Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| CN101537007A (zh) | 2009-03-18 | 2009-09-23 | 中国医学科学院血液病医院（血液学研究所） | N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用 |
| WO2010111653A2 (en) | 2009-03-27 | 2010-09-30 | The Uab Research Foundation | Modulating ires-mediated translation |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2011008830A1 (en) | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyrazine inhibitors of kinases |
| WO2011017513A1 (en) | 2009-08-07 | 2011-02-10 | Dow Agrosciences Llc | Pesticidal compositions |
| JP2011042639A (ja) | 2009-08-24 | 2011-03-03 | Kowa Co | ビフェニルピラジン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤 |
| CN101671336B (zh) | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 |
| DE102009043260A1 (de) | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
| CA2776690C (en) | 2009-10-06 | 2020-05-12 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as pdk1 inhibitors |
| WO2011060215A1 (en) * | 2009-11-13 | 2011-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer |
| CN102812006B (zh) | 2010-01-18 | 2016-01-20 | Mmv疟疾药物投资公司 | 新型抗疟疾试剂 |
| US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| WO2011124998A1 (en) | 2010-04-08 | 2011-10-13 | Pfizer Inc. | Substituted 3,5- di phenyl - isoxazoline derivatives as insecticides and acaricides |
| US20130030237A1 (en) | 2010-04-15 | 2013-01-31 | Charles Theuer | Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
| US8916593B2 (en) | 2010-05-04 | 2014-12-23 | Pfizer Inc. | Alkoxy-substituted 2-aminopyridines as ALK inhibitors |
| JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2569286B1 (en) | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| EP2569289A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| MX2012013081A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
| US9096584B2 (en) | 2010-05-12 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| MX2012013378A (es) | 2010-05-20 | 2013-01-24 | Hoffmann La Roche | Derivados de pirrolo [2, 3-b] pirazina-7-carboxamida y sus uso como inhibidores de cinasa janus (jak) y cinasa tirosina del brazo (syk). |
| WO2011144584A1 (en) | 2010-05-20 | 2011-11-24 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives as syk and jak inhibitors |
| WO2011163527A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| CN102311396B (zh) | 2010-07-05 | 2015-01-07 | 暨南大学 | 一种吡嗪类衍生物和其制备方法及在制药中的应用 |
| EP2407478A1 (en) | 2010-07-14 | 2012-01-18 | GENETADI Biotech, S.L. | New cyclotetrapeptides with pro-angiogenic properties |
| JP5782238B2 (ja) | 2010-07-30 | 2015-09-24 | ルネサスエレクトロニクス株式会社 | 電圧検出回路及びその制御方法 |
| JP5970003B2 (ja) | 2011-03-04 | 2016-08-17 | ローカス ファーマシューティカルズ インコーポレイテッド | アミノピラジン化合物 |
| US8440652B2 (en) | 2011-03-04 | 2013-05-14 | Lexicon Pharmaceuticals, Inc. | MST1 kinase inhibitors and methods of their use |
| JP2014510151A (ja) | 2011-04-05 | 2014-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ（ｔｒａｋｉｎａｓｅ）阻害剤として有用なアミノピラジン化合物 |
| JP2014513728A (ja) | 2011-05-17 | 2014-06-05 | プリンシピア バイオファーマ インコーポレイテッド | チロシンキナーゼ阻害剤としてのアザインドール誘導体 |
| JP2014520161A (ja) | 2011-06-22 | 2014-08-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| WO2012178124A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP3608316A1 (en) | 2011-09-30 | 2020-02-12 | Vertex Pharmaceuticals Incorporated | Deuterated derivatives of an inhibitor of atr kinase |
| WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013049859A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
| EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CA2850564A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2015502925A (ja) | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用なピラジン化合物 |
| WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| US8846918B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| IN2014KN02410A (Direct) | 2012-04-05 | 2015-05-01 | Vertex Pharma | |
| CN103373996A (zh) | 2012-04-20 | 2013-10-30 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的二并环衍生物 |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| PL3808749T3 (pl) | 2012-12-07 | 2023-07-10 | Vertex Pharmaceuticals Incorporated | Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych |
| EP3077397B1 (en) | 2013-12-06 | 2019-09-18 | Vertex Pharmaceuticals Inc. | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
| RU2020110358A (ru) | 2014-06-05 | 2020-04-30 | Вертекс Фармасьютикалз Инкорпорейтед | Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор- пиридин-3-ил]-пиразоло[1,5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы |
| JP6936007B2 (ja) | 2014-06-17 | 2021-09-15 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法 |
| US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
-
2013
- 2013-04-05 IN IN2410KON2014 patent/IN2014KN02410A/en unknown
- 2013-04-05 WO PCT/US2013/035466 patent/WO2013152298A1/en not_active Ceased
- 2013-04-05 HK HK15105707.6A patent/HK1205028A1/xx unknown
- 2013-04-05 HR HRP20171915TT patent/HRP20171915T1/hr unknown
- 2013-04-05 CA CA2869309A patent/CA2869309C/en active Active
- 2013-04-05 NZ NZ726671A patent/NZ726671A/en not_active IP Right Cessation
- 2013-04-05 EP EP17190136.6A patent/EP3311816A1/en not_active Withdrawn
- 2013-04-05 AU AU2013243291A patent/AU2013243291B2/en not_active Ceased
- 2013-04-05 RS RS20171287A patent/RS56673B1/sr unknown
- 2013-04-05 MX MX2014011908A patent/MX358818B/es active IP Right Grant
- 2013-04-05 ES ES13728551.6T patent/ES2654670T3/es active Active
- 2013-04-05 CN CN201810243995.2A patent/CN108478577A/zh active Pending
- 2013-04-05 LT LTEP13728551.6T patent/LT2833973T/lt unknown
- 2013-04-05 EP EP13728551.6A patent/EP2833973B1/en active Active
- 2013-04-05 NZ NZ720511A patent/NZ720511A/en not_active IP Right Cessation
- 2013-04-05 JP JP2015504748A patent/JP2015515478A/ja not_active Withdrawn
- 2013-04-05 US US13/857,658 patent/US20140044802A1/en not_active Abandoned
- 2013-04-05 SI SI201330879T patent/SI2833973T1/en unknown
- 2013-04-05 HU HUE13728551A patent/HUE035253T2/en unknown
- 2013-04-05 PL PL13728551T patent/PL2833973T3/pl unknown
- 2013-04-05 NZ NZ700580A patent/NZ700580A/en not_active IP Right Cessation
- 2013-04-05 CN CN201380018996.2A patent/CN104582795B/zh not_active Expired - Fee Related
- 2013-04-05 PT PT137285516T patent/PT2833973T/pt unknown
- 2013-04-05 DK DK13728551.6T patent/DK2833973T3/en active
- 2013-04-08 TW TW102112405A patent/TWI644672B/zh not_active IP Right Cessation
- 2013-04-08 TW TW106107579A patent/TW201740949A/zh unknown
- 2013-08-15 NO NO13829529A patent/NO2885404T3/no unknown
-
2015
- 2015-08-03 US US14/816,432 patent/US10478430B2/en active Active
-
2017
- 2017-07-25 JP JP2017143696A patent/JP6770490B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-24 AU AU2018200562A patent/AU2018200562A1/en not_active Abandoned
- 2018-06-08 JP JP2018110161A patent/JP2018150379A/ja not_active Withdrawn
-
2019
- 2019-07-10 US US16/507,139 patent/US11110086B2/en not_active Expired - Fee Related
-
2020
- 2020-08-27 JP JP2020143455A patent/JP2020196748A/ja not_active Withdrawn
-
2021
- 2021-08-03 US US17/444,318 patent/US20220233521A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2833973T1 (en) | Compounds useful as inhibitors of ATR kinase and their combination therapy | |
| JP2013526538A5 (Direct) | ||
| SI2376485T1 (en) | PIRAZINE DERIVATIVES USE AS ATR KINASE INHIBITORS | |
| JP2017186385A5 (Direct) | ||
| JP2013529199A5 (Direct) | ||
| IL263262A (en) | Atr kinase suppressant compounds, preparations containing them, their uses and methods for their preparation | |
| JP2013526540A5 (Direct) | ||
| JP2013529643A5 (Direct) | ||
| HRP20191375T1 (hr) | Postupak liječenja raka upotrebom kombinacije chk1 i atr inhibitora | |
| JP2013529200A5 (Direct) | ||
| JP2014510151A5 (Direct) | ||
| JP2015515478A5 (Direct) | ||
| JP2013526541A5 (Direct) | ||
| JP2012508260A5 (Direct) | ||
| JP2016512239A5 (Direct) | ||
| JP2016512816A5 (Direct) | ||
| JP2013526539A5 (Direct) | ||
| JP2016512815A5 (Direct) | ||
| CN108771681B (zh) | 作为dna-pk抑制剂的化合物及其氘化衍生物的共晶 | |
| JP2016501244A5 (Direct) | ||
| RU2012153675A (ru) | Соединения, пригодные в качестве ингибиторов atr киназы | |
| JP2018529713A5 (Direct) | ||
| US9464293B2 (en) | RNA aptamers for therapeutic and diagnostic delivery to pancreatic cancer cells | |
| RU2011123647A (ru) | Соединения, полезные в качестве ингибиторов atr киназы | |
| JP2018536649A5 (Direct) |